WaveBreak Therapeutics is focused on developing small-molecule drugs that target fleeting protein intermediates involved in neurodegenerative diseases, such as Parkinson's, Alzheimer's, and ALS, using a novel drug discovery platform based on biophysics
WaveBreak Therapeutics is focused on developing small-molecule drugs that target fleeting protein intermediates involved in neurodegenerative diseases, such as Parkinson's, Alzheimer's, and ALS, using a novel drug discovery platform based on biophysics.
WaveBreak Therapeutics is focused on developing small-molecule drugs that target fleeting protein intermediates involved in neurodegenerative diseases, such as Parkinson's, Alzheimer's, and ALS, using a novel drug discovery platform based on biophysics
WaveBreak Therapeutics is focused on developing small-molecule drugs that target fleeting protein intermediates involved in neurodegenerative diseases, such as Parkinson's, Alzheimer's, and ALS, using a novel drug discovery platform based on biophysics.